High potency improvements to weak aryl uracil HCV polymerase inhibitor leads

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 15, 2013, Pages 4367-4369

  Donner, Pamela ^a   Randolph, John T ^a   Huang, Peggy ^a   Wagner, Rolf ^a   Maring, Clarence ^a   Lim, Ben Hock ^a   Colletti, Lynn ^a   Liu, Yaya ^a   Mondal, Rubina ^a   Beyer, Jill ^a   Koev, Gennadiy ^a   Marsh, Kennan ^a   Beno, David ^a   Longenecker, Kenton ^a   Pilot Matias, Tami ^a   Kati, Warren ^a   Molla, Akhter ^a   Kempf, Dale ^a  

^a ABBVIE INC   (United States)

Author keywords

Aryl uracil; HCV; NS5B polymerase

Indexed keywords

ANTIVIRUS AGENT; ARYL URACIL; NONSTRUCTURAL PROTEIN 5B; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME INHIBITION; HEPATITIS C VIRUS; NONHUMAN; RAT; REPLICON;

ANIMALS; ANTIVIRAL AGENTS; HALF-LIFE; HEPACIVIRUS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84879692873     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.05.078     Document Type: Article

References (5)

1. WHO, Hepatitis C. Fact Sheet No. 164. Revised October 2000.
2. W.R. Kim Hepatology 36 2002 30
3. S. Pol, and V.O. Mallet Expert Opin. Biol. Ther. 6 2006 923
4. C. Rice Nature 474 2011 S8
5. Y. Liu, B.H. Lim, W.W. Jiang, C.A. Flentge, D.K. Hutchinson, D.L. Madigan, J.T. Randolph, R. Wagner, C.J. Maring, W.M. Kati, and A. Molla Bioorg. Med. Chem. Lett. 22 2012 3747